利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.027 秒)

    Diacylglycerol O-acyltransferase 2α (DGAT2α)
    1.
    发明授权
    Diacylglycerol O-acyltransferase 2α (DGAT2α) 有权
    二酰基甘油O-酰基转移酶2α（DGAT2α）

    公开(公告)号：US07862819B2

    公开(公告)日：2011-01-04

    申请号：US10446441

    申请日：2003-05-27

    申请人： Sylvaine Cases ,  Robert V. Farese ,  Scot J. Stone ,  Ping Zhou

    发明人： Sylvaine Cases ,  Robert V. Farese ,  Scot J. Stone ,  Ping Zhou

    IPC分类号： A61K39/395 ,  C12N9/10 ,  C12N15/09

    CPC分类号： C12N9/1029 ,  A01K2217/05 ,  A61K38/00 ,  A61K2039/505 ,  C12Y203/0102 ,  C12Y203/01022

    摘要： Nucleic acid compositions encoding mammalian DGAT2α polypeptide products with diglyceride acyltransferase activity, as well as the mammalian DGAT2α polypeptide products encoded thereby and methods for producing the same, are provided. The subject DGAT2α polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies and in the production of triacylglycerols.

    摘要翻译： 提供了编码具有甘油二酯酰基转移酶活性的哺乳动物DGAT2α多肽产物的核酸组合物，以及由此编码的哺乳动物DGAT2α多肽产物及其制备方法。 主题DGAT2α多肽和核酸组合物可用于各种应用，包括研究，诊断和治疗剂筛选应用，以及治疗疗法和三酰基甘油的生产。

    Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
    2.
    发明授权
    Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof 失效
    二酰基甘油酰基转移酶基因中的多态性及其使用方法

    公开(公告)号：US06911539B2

    公开(公告)日：2005-06-28

    申请号：US10142516

    申请日：2002-05-08

    申请人： Erwin H. Ludwig ,  Robert V. Farese ,  Thomas L. Innerarity ,  Sylvaine Cases

    发明人： Erwin H. Ludwig ,  Robert V. Farese ,  Thomas L. Innerarity ,  Sylvaine Cases

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P19/34

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： The present invention provides isolated an polynucleotide comprising a polymorphic nucleotide sequence from a diacylglycerol acyltransferase (DGAT) gene, wherein at least one a polymorphism is associated with a condition relating to DGAT activity. The invention further provides diagnostic assays for detecting the presence in a nucleic acid sample of a polymorphism in a DGAT gene that is associated with a condition relating to DGAT activity, and for detecting a propensity to develop a condition associated with DGAT activity. The invention further provides treatment methods.

    摘要翻译： 本发明提供了分离的多核苷酸，其包含来自二酰基甘油酰基转移酶（DGAT）基因的多态性核苷酸序列，其中至少一个多态性与与DGAT活性相关的病症相关。 本发明还提供了用于检测在与DGAT活性有关的病症相关的DGAT基因的核酸样品中存在多态性的诊断测定，以及用于检测发展与DGAT活性相关的病症的倾向。 本发明还提供了治疗方法。

    Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
    3.
    发明授权
    Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof 有权
    二酰基甘油酰基转移酶基因中的多态性及其使用方法

    公开(公告)号：US06444427B1

    公开(公告)日：2002-09-03

    申请号：US09613444

    申请日：2000-07-11

    申请人： Erwin H. Ludwig ,  Robert V. Farese ,  Thomas L. Innerarity ,  Sylvaine Cases

    发明人： Erwin H. Ludwig ,  Robert V. Farese ,  Thomas L. Innerarity ,  Sylvaine Cases

    IPC分类号： C12Q168

    CPC分类号： C12Q1/6883 ,  C12Q2600/156

    摘要： The present invention provides isolated an polynucleotide comprising a polymorphic nucleotide sequence from a diacylglycerol acyltransferase (DGAT) gene, wherein at least one a polymorphism is associated with a condition relating to DGAT activity. The invention further provides diagnostic assays for detecting the presence in a nucleic acid sample of a polymorphism in a DGAT gene that is associated with a condition relating to DGAT activity, and for detecting a propensity to develop a condition associated with DGAT activity. The invention further provides treatment methods.

    摘要翻译： 本发明提供了分离的多核苷酸，其包含来自二酰基甘油酰基转移酶（DGAT）基因的多态性核苷酸序列，其中至少一个多态性与与DGAT活性相关的病症相关。 本发明还提供了用于检测在与DGAT活性有关的病症相关的DGAT基因的核酸样品中存在多态性的诊断测定，以及用于检测发展与DGAT活性相关的病症的倾向。 本发明还提供了治疗方法。

    Treatment of obesity, metabolic syndrome, and diabetes with protein kinase C inhibitors
    5.
    发明授权
    Treatment of obesity, metabolic syndrome, and diabetes with protein kinase C inhibitors 有权
    用蛋白激酶C抑制剂治疗肥胖症，代谢综合征和糖尿病

    公开(公告)号：US08580769B2

    公开(公告)日：2013-11-12

    申请号：US13417075

    申请日：2012-03-09

    申请人： Robert V. Farese

    发明人： Robert V. Farese

    IPC分类号： A61K31/675 ,  A61K31/28 ,  A61K31/4164 ,  A61K31/155

    CPC分类号： A61K31/4164 ,  A61K31/155 ,  A61K31/29 ,  A61K31/66 ,  A61K31/7135 ,  A61K45/06 ,  A61K2300/00

    摘要： Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C (PKC)-ι, thereby treating the obesity, metabolic syndrome, or diabetes in the subject. In some embodiments the compound that specifically inhibits hepatic PKC-ι includes a thio-gold compound (such as aurothiomalate, aurothioglucose, and auranofin) or a derivative thereof, or a pharmaceutically acceptable salt thereof. In other embodiments, the compound that specifically inhibits hepatic PKC-ι includes 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-[1R-(1α,2β,3β,4α)] (ICAPP) or a derivative thereof, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本文公开了治疗肥胖，代谢综合征，糖尿病或这些病症的组合的方法。 所述方法包括选择患有肥胖，代谢综合征或糖尿病的受试者，并向受试者施用治疗有效量的包含特异性抑制肝蛋白激酶C（PKC）的化合物的组合物，从而治疗肥胖，代谢综合征， 或糖尿病。 在一些实施方案中，特异性抑制肝脏PKC-iota的化合物包括硫代金化合物（例如亚硫辛酸，亚硫代葡萄糖和泛酰诺芬）或其衍生物或其药学上可接受的盐。 在其它实施方案中，特异性抑制肝脏PKC-iota的化合物包括1H-咪唑-4-甲酰胺，5-氨基-1- [2,3-二羟基-4 - [（膦酰氧基）甲基]环戊基] - [1R-（ 1α，2beta，3beta，4alpha）]（ICAPP）或其衍生物或其药学上可接受的盐。

    TREATMENT OF OBESITY, METABOLIC SYNDROME, AND DIABETES WITH PROTEIN KINASE C INHIBITORS
    7.
    发明申请
    TREATMENT OF OBESITY, METABOLIC SYNDROME, AND DIABETES WITH PROTEIN KINASE C INHIBITORS 有权
    用蛋白激酶C抑制剂治疗肥胖，代谢综合征和糖尿病

    公开(公告)号：US20120232037A1

    公开(公告)日：2012-09-13

    申请号：US13417075

    申请日：2012-03-09

    申请人： Robert V. Farese

    发明人： Robert V. Farese

    IPC分类号： A61K31/675 ,  A61K31/28 ,  A61P3/06 ,  A61P3/04 ,  A61P3/00 ,  A61P3/10 ,  A61K31/4164 ,  A61K31/155

    CPC分类号： A61K31/4164 ,  A61K31/155 ,  A61K31/29 ,  A61K31/66 ,  A61K31/7135 ,  A61K45/06 ,  A61K2300/00

    摘要： Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C (PKC)-τ, thereby treating the obesity, metabolic syndrome, or diabetes in the subject. In some embodiments the compound that specifically inhibits hepatic PKC-τ includes a thio-gold compound (such as aurothiomalate, aurothioglucose, and auranofin) or a derivative thereof, or a pharmaceutically acceptable salt thereof. In other embodiments, the compound that specifically inhibits hepatic PKC-τ includes 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-[1R-(1α,2β,3β,4α)] (ICAPP) or a derivative thereof, or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本文公开了治疗肥胖，代谢综合征，糖尿病或这些病症的组合的方法。 所述方法包括选择患有肥胖，代谢综合征或糖尿病的受试者，并向受试者施用治疗有效量的包含特异性抑制肝蛋白激酶C（PKC）-τ的化合物的组合物，由此治疗肥胖症，代谢综合征， 或糖尿病。 在一些实施方案中，特异性抑制肝脏PKC-τ的化合物包括硫代金化合物（例如硫代 - 硫代葡萄糖苷，氨基硫代葡萄糖和奥拉芬芬）或其衍生物或其药学上可接受的盐。 在其他实施方案中，特异性抑制肝PKC-τ的化合物包括1H-咪唑-4-甲酰胺，5-氨基-1- [2,3-二羟基-4 - [（膦酰氧基）甲基]环戊基] - [1R-（ 1α，2＆bgr;，3＆bgr，4α）]（ICAPP）或其衍生物或其药学上可接受的盐。